Accumulating evidence indicates that partial Drp1 inhibition is protective in experimental models of neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS) [5, 6]. Here, DNM1L is linked to Huntington disease.